DE60233656D1 - Pyridylcyanoguanidin verbindungen - Google Patents

Pyridylcyanoguanidin verbindungen

Info

Publication number
DE60233656D1
DE60233656D1 DE60233656T DE60233656T DE60233656D1 DE 60233656 D1 DE60233656 D1 DE 60233656D1 DE 60233656 T DE60233656 T DE 60233656T DE 60233656 T DE60233656 T DE 60233656T DE 60233656 D1 DE60233656 D1 DE 60233656D1
Authority
DE
Germany
Prior art keywords
halogen
alkylcarbonyl
aminoalkyl
formyl
alkoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233656T
Other languages
English (en)
Inventor
Fredrik Bjoerkling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Application granted granted Critical
Publication of DE60233656D1 publication Critical patent/DE60233656D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
DE60233656T 2001-05-24 2002-05-24 Pyridylcyanoguanidin verbindungen Expired - Lifetime DE60233656D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29292801P 2001-05-24 2001-05-24
US29292701P 2001-05-24 2001-05-24
PCT/DK2002/000353 WO2002094813A1 (en) 2001-05-24 2002-05-24 Novel pyridyl cyanoguanidine compounds

Publications (1)

Publication Number Publication Date
DE60233656D1 true DE60233656D1 (de) 2009-10-22

Family

ID=26967641

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233656T Expired - Lifetime DE60233656D1 (de) 2001-05-24 2002-05-24 Pyridylcyanoguanidin verbindungen

Country Status (18)

Country Link
US (2) US7304066B2 (de)
EP (1) EP1397355B1 (de)
JP (1) JP4429607B2 (de)
KR (1) KR20030097897A (de)
CN (1) CN1247570C (de)
AT (1) ATE442362T1 (de)
BR (1) BR0209930A (de)
CA (1) CA2447021C (de)
CZ (1) CZ20033190A3 (de)
DE (1) DE60233656D1 (de)
ES (1) ES2328799T3 (de)
HK (1) HK1066216A1 (de)
HU (1) HUP0400021A3 (de)
IL (1) IL158574A0 (de)
MX (1) MXPA03010669A (de)
PL (1) PL366459A1 (de)
RU (1) RU2292344C2 (de)
WO (1) WO2002094813A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US7304086B2 (en) * 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8053446B2 (en) * 2004-12-22 2011-11-08 Leo Pharma A/S Cyanoguanidine compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2007005534A2 (en) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
WO2010023307A1 (en) 2008-08-29 2010-03-04 Topotarget A/S Novel urea and thiourea derivatives
EP2394649A4 (de) * 2009-02-06 2012-08-15 Tianjin Hemay Bio Tech Co Ltd Pharmazeutische zusammensetzungen mit pyridylcyanoguanidinen, herstellungsverfahren dafür und ihre verwendung
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011095027A1 (zh) * 2010-02-04 2011-08-11 天津和美生物技术有限公司 吡啶基氰基胍衍生物
CN102740850B (zh) * 2010-02-04 2014-04-02 天津和美生物技术有限公司 吡啶基氰基胍衍生物
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
WO2012031199A1 (en) * 2010-09-03 2012-03-08 Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of nampt
WO2012055346A1 (zh) 2010-10-26 2012-05-03 天津和美生物技术有限公司 N-(6-(4-氯苯氧基)己基)-n'-氰基-n''-(4-吡啶基)胍的多晶型物及其制备和应用
WO2012077108A1 (en) * 2010-12-09 2012-06-14 Radikal Therapeutics Inc. Multifunctional nitroxide derivatives and uses thereof
KR102117982B1 (ko) * 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
KR101656663B1 (ko) 2015-07-27 2016-09-13 충남대학교산학협력단 암 예방 및 치료용 조성물
CN110734405A (zh) * 2019-11-11 2020-01-31 华东数字医学工程研究院 一种n-(6-氨己基)-n’-甲基-2,2’-联咪唑的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696140A (en) * 1992-09-15 1997-12-09 Leo Pharmaceutical Products Ltd. N-cyano-N'-pyridylguanidines as serotonin antagonists
GB9219472D0 (en) * 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711122D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US7129043B1 (en) * 1998-10-22 2006-10-31 Duke University Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
EP1198456B1 (de) 1999-08-03 2007-09-19 Abbott Laboratories Kalium kanalaktivatoren

Also Published As

Publication number Publication date
IL158574A0 (en) 2004-05-12
US20040220408A1 (en) 2004-11-04
HUP0400021A2 (hu) 2004-04-28
HK1066216A1 (en) 2005-03-18
PL366459A1 (en) 2005-02-07
JP2005508859A (ja) 2005-04-07
EP1397355B1 (de) 2009-09-09
CZ20033190A3 (cs) 2004-06-16
JP4429607B2 (ja) 2010-03-10
ES2328799T3 (es) 2009-11-18
CN1247570C (zh) 2006-03-29
EP1397355A1 (de) 2004-03-17
BR0209930A (pt) 2004-03-30
CA2447021A1 (en) 2002-11-28
KR20030097897A (ko) 2003-12-31
ATE442362T1 (de) 2009-09-15
RU2292344C2 (ru) 2007-01-27
HUP0400021A3 (en) 2008-03-28
CA2447021C (en) 2010-08-10
US7304066B2 (en) 2007-12-04
WO2002094813A1 (en) 2002-11-28
US7807682B2 (en) 2010-10-05
MXPA03010669A (es) 2004-07-01
US20080090842A1 (en) 2008-04-17
CN1509283A (zh) 2004-06-30
RU2003137007A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
ATE442362T1 (de) Pyridylcyanoguanidin verbindungen
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
ATE302775T1 (de) Carbolinderivate
MY135841A (en) Novel benzodioxoles
HK1095138A1 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
MXPA05009359A (es) Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6.
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
HK1080470A1 (en) Heterocyclic compounds
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
IS6902A (is) N-setin heterósýklísk NMDA/NR2B mótlyf sem ekki eru arýl
HK1121440A1 (en) Biphenyl derivatives and their use in treating hepatitis c
RS20050174A (en) -3(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
ATE346067T1 (de) Carbolinderivate
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
AU2002213421A1 (en) Condensed pyridoindole derivatives
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
MXPA03002909A (es) Compuestos quimicos.
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
IE960775L (en) Arylalkylamine having anticonvulsant and neuroprotective properties
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition